Kangpei Biotech Announces Board Resolution on Issuance of Restricted Stock Units for 2025 Fiscal Year
Key facts
- Kangpei Biotech Announces Board Resolution on Issuance of Restricted Stock Units for 2025 Fiscal Year
- Kangpei Biotech Co., Ltd. has resolved to issue 23,000 new restricted stock units for its employees for the 2025 fiscal year, with the capital increase base date set as June 26, 2026.
- Source: PR Times
- Date: June 26, 2026
Direct answer
Kangpei Biotech Co., Ltd. has resolved to issue 23,000 new restricted stock units for its employees for the 2025 fiscal year, with the capital increase base date set as June 26, 2026.
- Citation
- Kangpei Biotech Announces Board Resolution on Issuance of Restricted Stock Units for 2025 Fiscal Year (June 26, 2026), PR Times
- Source
- PR Times
- Date
- June 26, 2026
Kangpei Biotech Co., Ltd. has resolved to issue 23,000 new restricted stock units for its employees for the 2025 fiscal year, with the capital increase base date set as June 26, 2026.
📋 Article Processing Timeline
- 📰 Published: June 26, 2026 at 09:00
- 🔍 Collected: June 27, 2026 at 17:00 (32h 0m after Published)
- 🤖 AI Analyzed: June 27, 2026 at 18:20 (1h 20m after Collected)
1. Event Date: June 26, 2026
2. Company Name: Kangpei Biotech Co., Ltd.
3. Relationship with Company: Parent Company
4. Cross-shareholding Ratio: Not applicable
5. Reason for Event:
(1) The issuance was approved by the 2025 Annual General Meeting and authorized by the Financial Supervisory Commission of the Executive Yuan under document number JGZ-1140349351 dated July 4, 2025.
(2) The board of directors resolved on June 26, 2026, to issue 23,000 restricted stock units for the 2025 fiscal year, with a par value of NT$0.5 per share. The capital increase base date is June 26, 2026. Any adjustments due to operational changes will be delegated to the Chairman.
(3) All restrictions, key agreements, and supplementary matters related to the issuance shall be governed by relevant laws and regulations and the company's "2025 Restricted Stock Unit Issuance Guidelines."
6. Mitigation Measures: None
7. Other Disclosures:
This announcement qualifies as material information under Article 7, Paragraph 9, Clause 9 of the Enforcement Rules of the Securities and Exchange Act, if applicable to publicly issued companies, but no additional matters are currently required.
2. Company Name: Kangpei Biotech Co., Ltd.
3. Relationship with Company: Parent Company
4. Cross-shareholding Ratio: Not applicable
5. Reason for Event:
(1) The issuance was approved by the 2025 Annual General Meeting and authorized by the Financial Supervisory Commission of the Executive Yuan under document number JGZ-1140349351 dated July 4, 2025.
(2) The board of directors resolved on June 26, 2026, to issue 23,000 restricted stock units for the 2025 fiscal year, with a par value of NT$0.5 per share. The capital increase base date is June 26, 2026. Any adjustments due to operational changes will be delegated to the Chairman.
(3) All restrictions, key agreements, and supplementary matters related to the issuance shall be governed by relevant laws and regulations and the company's "2025 Restricted Stock Unit Issuance Guidelines."
6. Mitigation Measures: None
7. Other Disclosures:
This announcement qualifies as material information under Article 7, Paragraph 9, Clause 9 of the Enforcement Rules of the Securities and Exchange Act, if applicable to publicly issued companies, but no additional matters are currently required.
FAQ
How does Kangpei's stock issuance affect shareholders?
It may dilute ownership, but aims to secure talent for long-term growth.
What are restricted stock units?
Shares granted to employees with vesting conditions based on tenure or performance.
Where is Kangpei Biotech based?
The company is headquartered in Taipei, Taiwan, focusing on biopharmaceutical innovation.